Advertisement

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Varsha Gandhi, PhD, on Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Sep
15
Today In Oncology
Novel ADC Under Study in Previously Treated EGFR-Mutated NSCLC
New Subcutaneous Amivantamab Combo Dosing Schedule Shows Safety and Efficacy in EGFR-Positive NSCLC
STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach
Hypofractionated vs Conventional Radiotherapy in Phase III Trial for LS-SCLC
Tarlatamab and Anti-PD-1 Therapy as First-Line Maintenance for ES-SCLC
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo